Abstract Cancers of the oesophagus, gastro-oesophageal junction and stomach (upper gastrointestinal tract cancers; UGICs) pose a major health risk around the world. Collectively, the 5-year survival rate has remained <15%, and therapeutic improvements have been very slow and small. Novel molecules for early diagnosis, prognosis and therapy are, therefore, urgently needed. The role that microRNA (miRNA) molecules have in UGICs are worth pursuing to this end. miRNAs are small noncoding RNA molecules that regulate ~60% of coding genes in humans and, therefore, are pivotal in mediating and regulating many physiologic processes. miRNAs are deregulated in many disease states, particularly in cancer, making them important targets. Here, we review the growing body of evidence regarding the alterations of miRNAs in UGICs. By suppressing translation and/or promoting degradation of mRNAs, miRNAs can contribute to carcinogenesis and progression of UGICs. In-depth studies of miRNAs in UGICs might yield novel insights and potential novel therapeutic strategies.
Introduction
Cancers of the upper gastrointestinal tract (UGICs) include those originating in the oesophagus, gastrooesophageal junction and stomach. The incidence of adenocarcinoma involving the lower third of the oesophagus, gastro-oesophageal junction and proximal stomach has risen considerably in the past 30 years. 1 It is estimated that 38,780 new cases and 25,610 deaths are likely to occur from UGICs in 2012 in the USA alone. 2 Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death in the world. 3 Helicobacter pylori infection, gastrin levels, germline mutations, dietary factors and other chronic gastric conditions are all factors involved in the development of gastric cancer.
Our understanding of the molecular basis of carcinogenesis and progression of UGICs has lagged behind that of many other tumour types. This knowledge deficit is creating a barrier in the development of effective therapies, and progress in the treatment of UGICs has been unsatis factory and slow. Consequently, outcomes for patients with UGICs have remained dismal, with 5-year survival rates <15%. 2 Improved understanding of the role of microRNAs (miRNAs) in UGICs could lead to novel prevention strategies, early detection and improved therapeutics.
MicroRNAs miRNAs are short (20-24 nucleotides) stable RNA molecules that are not translated into proteins but regulate 60% of coding genes by binding to mRNA molecules and so preventing their translation and/or promoting their degradation. More than 1,000 miRNAs have been identified, and they are involved in nearly all physio logic processes, as well as having an important role in diseases, such as cancer. Novel functions and mechanisms by which miRNAs regulate genes are constantly being discovered. [4] [5] [6] Genes that encode miRNAs are located in intergenic regions but can also be in exonic or intronic regions of other genes. 7 In addition, miRNA genes can be found in the introns of protein-coding or non-protein-coding genes. 8 Each miRNA can target a large number of genes (mRNAs), and each mRNA can be targeted by several miRNAs. 9 The many ways in which miRNAs engage mRNA have been described and new mechanisms are regularly being discovered. 8 Most commonly, miRNAs either degrade an mRNA (when perfect complementarity is established) or inhibit its translation (when imperfect complementarity is established); the net outcome is a reduction in the amount of a particular protein inside the cell. 4, 10 In addition, some miRNAs can directly bind to the (open reading frame of the) DNA or modify the methylation status of a gene. 11 A mature miRNA can target mRNA binding proteins (functioning like a decoy). 12 The genes that encode miRNAs are frequently located inside or close to fragile sites of chromosomes and are subject to considerable deregulation in cancer. 10 Alterations in the expression of miRNAs in cancer are related to deletions, mutations, polymorphisms, promoter hypermethylation and/or histone acetylation of miRNA genes as well as alterations in the miRNA processing machinery. Amplifications, translocations and/ or transcript activations can also lead to changes in expression of miRNAs.
Many miRNAs have been identified to act as oncogenes, tumour suppressors and important modulators in cellular pathways. The oncogenic or tumour suppressor function of an miRNA depends on the role of the target mRNA. Increased activity of oncogenic miRNAs (oncomiRs) leads to inhibition of tumour suppressor genes, facilitating cell proliferation and tumour progression. Decreased activity of tumour-suppressor miRNAs (tsmiRs) leads to increased oncogene translation, contributing to tumour formation. 13 Certain miRNAs are involved in the regulation of metastasis (metastamiRs); these miRNAs can positively or negatively regulate cancer cell migration, invasion and metastasis. 14, 15 Some miRNAs are upregulated or downregulated in specific types of cancer, for example miR-122 in hepatocellular carcinoma. 16, 17 Further research might yield tissue-specific miRNAs; a level of specificity that would enable tumour-type-specific targeting. Some miRNAs are actively secreted in blood and other body fluids and could potentially be used for the early diagnosis Key points ■ Cancers of the oesophagus, gastro-oesophageal junction and stomach (UGICs) are common worldwide, and outcomes for patients with these cancers have remained dismal ■ miRNAs are noncoding, single-stranded RNAs ~22 nucleotides in length; they comprise a novel class of gene regulators that negatively regulate their targets ■ Many miRNA that act as oncogenes, tumour suppressors and important modulators in the process of invasion and metastasis of UGICs have been identified ■ Increased activity of oncogenic miRNAs leads to inhibition of tumour suppressor genes, facilitating cell proliferation and tumour progression; decreased activity of tumour-suppressor miRNAs leads to increased oncogene translation, contributing to tumour progression ■ Certain miRNAs are involved in the regulation of metastasis as well as in modulation of chemoresistance in UGICs ■ Circulating miRNAs provide potential biomarkers for early diagnosis and prognosis in patients with UGICs; further research could lead to exploitation of miRNAs as therapeutic or diagnostic targets for these cancers of cancer and monitoring of therapy; some circulating miRNAs have been described in UGICs. 18 Some miRNAs participate in genetic exchange among cells. 19 miRNA profiling can make a distinction between normal and malignant tissue 7 but, more importantly, since tumourtype-specific miRNA profiles (miRNomes) have been discovered, such observations lend themselves to establishing miRNomics as a diagnostic tool for uncovering the origin of tumours. 8 For example, as described above, miR-122 seems to be highly enriched in the liver, suggesting that the discovery of more organ-specific miRNAs could improve our ability to target these processes. 20 For greater understanding of the mechanisms of deregulated miRNA, we recommend a previous report. 21 
miRNAs and oesophageal cancer
Microarray or real-time PCR and in situ hybridization have been used to determine and validate the expression of miRNAs in cell lines and tumour specimens. Many reports have described deregulated miRNAs and their targets and functions in the major oesophageal cancer histo logic subtypes: oesophageal adenocarcinoma (Table 1 ) and oesophageal squamous cell carcinoma ( Table 2) . 22 
Oesophageal adenocarcinoma
OncomiRs miRNA profiling and functional studies have been used to understand the mechanisms of progression of Barrett oesophagus to oesophageal adenocarcinoma. Several reports discuss the alterations in miRNAs in Barrett oesophagus and oesophageal adenocarcinoma and have identified targets and characterized their functional roles in the carcinogenesis of oesophageal adeno carcinoma. For example, miR-106b-25 polycistron is progressively upregulated in high-risk Barrett oesophagus to oesopha geal adenocarcinoma; this upregulation is associated with genomic amplification and overexpression of MCM7 locus at chromosome 7q22.1. 23 The upregulated polycistron targets and inhibits P21 and Bim proteins, which affect the cell cycle and apoptosis, thereby contributing to oesophageal adenocarcinoma carcinogenesis. 23 Two independent reports have described upregulation of miR-196a in a progressive manner from Barrett oesophagus to Barrett oesophagus with dysplasia and finally to oesophageal adenocarcinoma; miR-196a targets ANXA1 (annexin A1), SPRR2C (small prolinerich protein 2C) and S100A9. 24, 25 Expression of PDCD4 (programmed cell death receptor 4), a tumour suppressor gene, decreased progressively and substantially with progression of Barrett oesophagus to oesophageal adenocarcinoma, but miR-21 expression was upregulated in high-grade dysplasia with Barrett oesophagus and oesophageal adeno carcinoma, which is consistent with PDCD4 deregulation; functional studies have confirmed that miR-21 is a negative regulator of PDCD4 in vivo and has an oncogenic role in oesophageal adenocarincoma. 26 Therefore, miR-21, miR-196a, and miR-192, which are upregulated in oesophageal adenocarcinoma but not in normal samples, have been termed as oncomiRs. 27 ,28 tsmiRs Two miRNA alterations have been identified that might mediate progression to oesophageal adenocarcinoma: miR-31 showed frequent downregulation only in highgrade dysplasia and oesophageal adenocarcinoma cases, suggesting an association with transition from Barrett metaplasia to high-grade dysplasia, whereas miR-375 showed marked downregulation exclusively in oesopha geal adenocarcinomas but not in Barrett metaplasia or lesions with high-grade dysplasia, suggesting an association with progression to invasive carcinoma. 29 Therefore, miR-31 and miR-375 have been proposed to be specifically associated with early and late-stage malignant progression, respectively. 29 However, documenting the functional significance of such discoveries is difficult in this setting because of the lack of mature genetically engineered mouse models. Some of the work is, therefore, preliminary. For example, several studies have found alterations in miRNAs in Barrett oesophagus and oesophageal adenocarcinoma, but the target mRNAs have not been identified.
Smith et al. 30 found that miR-200 family members were downregulated in oesophageal adeno carcinoma when compared with Barrett oesophagus, and a significant inverse correlation was noted between miR-200 family expression and ZEB1 (zinc finger E-box binding homeobox 1) and ZEB2 expression in Barrett oesopha gus and oesophageal adenocarcinoma. miR-203, miR-205, Let-7a/b/c, miR-345, miR-494, miR-193a and miR-375 are downregulated in oesophageal adeno carcinoma and could also be considered as tsmi RNAs. 28, [31] [32] [33] [34] In-depth studies of these miRNAs will be important for their potential development as therapeutic targets. 
REVIEWS Oesophageal squamous cell carcinoma
OncomiRs A large number of miRNAs and their targets have been identified that are upregulated in oesophageal squamous cell carcinoma. These oncomiRs target important tumour suppressors. miR-21 has been reported by several independent groups to be an important oncomiR in oesophageal squamous cell carcinoma. [35] [36] [37] miR-21 targets PTEN (phosphatase and tensin homolog) and PDCD4 and seems to promote progression of oesophageal squamous cell carcinoma; miR-21 should be explored as a therapeutic target for preclinical or clinical trials for subset of patients with high expression levels of this miRNA. Two reports note an upregulation of miR-25 and miR-92a in oesophageal squamous cell carcinoma, both of which target CDH1. This gene encodes E-cadherin, which is an important protein for maintaining a normal epithelial phenotype-its downregulation can lead to epithelial-mesenchymal transition (EMT) and metastasis. 38, 39 Both miRNAs promote migration and invasion through reduced expression of E-cadherin and are associated with poor prognosis. 38, 39 Upregulation of miR-10b has been reported in 95% of oesophageal squamous cell carcinomas, along with reduced expression of KLF4 (Krüppel-like factor 4), an important tumour suppressor in the gastrointestinal tract.
40 LATS2 (large tumour suppressor homolog 2) is a member of the LATS tumour suppressor family and is involved in Hippo signalling, which controls organ size and has a crucial role in liver and gastrointestinal tract carcinogenesis. Frequent loss of heterozygosity of LATS has been reported in human oesophageal cancers, and miR-373 inhibits LATS2 in vitro and in vivo. 41 Therefore, miR-373 might have an oncogenic role worthy of further research for potential therapeutic value. 41 Many more potential oncogenic miRNAs have been reported in oesophageal squamous cell carcinoma ( Figure 1 , Table 2 ).
22,24,42-48
tsmiRs Similarly, many downregulated miRNAs and their targets have been identified in oesophageal squamous cell carci noma. Among these, miR-375 is the most promising tsmiR that is consistently down regulated either in tumour tissues or plasma from patients with oesophageal squamous cell carcinoma compared with healthy controls. 27, [49] [50] [51] Hypermethylation of the miR-375 promoter is the reported mechanism of its down regulation.
51 IGF1R (insulin-like growth factor 1 receptor) and PDK1 (phospho inositide-dependent kinase 1) are important components of the IGF1 and phosphatidyl inositol 3-kinase (PI3K) pathways, which are frequently over expressed in many malignancies and have a crucial role in promoting cell proliferation, survival and meta stasis; 49 miR-375 might interact with the 3'-untranslated regions of IGF1R and PDK1 and downregulate their expression. Therefore, IGF1R and PDK1 are two major targets of miR-375. 49, 51 Another report suggests that miR-133a inhibits tumorigenesis and growth in vivo and inhibits CD47; overexpression of CD47 correlates with poor prog nosis.
52 miR-133a in concert with miR-145 and miR-133b target FSCN1 (actin-binding oncogenic protein, Fascin homolog1) and thereby inhibit cell proliferation and invasion in oesophageal sqaumous cell carcinoma cells. 53 An in vitro study by Matsushima et al. 54 demonstrated that the downregulation of miR-205 results in reduced cell ular invasion and migration by targeting ZEB2; it also reduces EMT by decreasing E-cadherin expression. 54, 55 Let-7a and miR-34a, reportedly involved in cancer stem cell regulation, 6 are downregulated in oesophageal squamous cell carcinoma. [56] [57] [58] Further tsmiRs include: miR-29c, which targets cyclin E without affecting cyclin dependent kinase (CDK)-2 and CDK6; 59 miR-210, which targets FGFRL1; 60 and miR-223, which targets ARTN 61 ( Table 2) . 62 miRNAs and gastric cancer OncomiRs Many overexpressed oncomiRs affect apoptosis and proliferation in gastric cancer. Overexpression of miR-181a in a gastric cancer cell line led to increased cell proliferation and inhibition of apoptosis by repression of tumour suppressor KLF6. 63 Several investigators have reported upregulation of miR-21 in gastric cancer (its targets, as mentioned above, are PDCD4 and PTEN). [64] [65] [66] miR-196a/196b are markedly overexpressed in tumour tissues and serum of patients with gastric cancer. 67, 68 miR-146a in gastric cancer directly targets SMAD4; and ectopic expression of miR-146a might increase proliferation and inhibit apoptosis of gastric cancer cells. 69 Overexpression of miR-191 has been reported in the gastric cancer cell line MGC803 and in gastric cancer tissue; this miRNA regulates NDST1 (N-deacetylase/ N-sulphotransferase 1). 70 Overexpression of miR-370 in gastric cancer tissue has also been observed, leading to downregulation of TGFBR2 (TGFβ type II receptor). 71 miR-126 overexpression leads to inhibition of SOX2, which seems to contribute to gastric cancer carcinogenesis. 72 Thus it seems that many oncomiRs are worthy Figure 1 | miRNAs, targets and functions in oesophageal cancers. *Common in both oesophageal adenocarcinoma and oesophageal squamous cell carcinoma. Abbreviations: EMT, epithelial-mesenchymal transition; miRNA, microRNA; oncomiRs, oncogenic miRNAs; tsmiRs, tumour suppressor miRNAs.
REVIEWS
of further research and might become thera peutic targets in the future. More oncomiRNAs in gastric cancer are shown in Figure 2 and Table 3 .
73-78
tsmiRs miR-181b and miR-182 are substantially downregulated in human gastric adenocarcinoma tissue samples compared with the adjacent normal gastric tissues. 79, 80 Functionally, overexpression of miR-181b suppressed the proliferation and colony formation rate of gastric cancer cells and decreased the expression of CREB1 (cAMP responsive element binding protein 1) by binding to its 3' untranslated region. Thus, miR-181b and miR-182 might function as tumour suppressors in gastric adeno carcinoma cells through negative regulation of CREB1. 79, 80 Carvalho et al. 81 found that miR-101 was downregulated in gastric cancer owing to microdeletions at miR-101 genomic loci that subsequently led to EZH2 overexpression and CDH1 dysfunction, especially in intestinal-type gastric cancer. miR-124 inhibits gastric cancer cell proliferation by inducing the cell cycle inhibitors P21 and P27 by targeting oncogenic SPHK1.
82
The miR-409-3p cluster also inhibits proliferation by targeting the transcriptional regulator PHF10. 83 MYC, an important modulator of cell growth and apoptosis, is downregulated by miR-429. 84 miR-296 is progressively lost during tumour progression, leading to aberrant overexpression of SCRIB. 85 
miR-375 is downregulated in gastric cancer and its targets are the oncogenes JAK2, PDK1 and YWHAZ (14-3-3 zeta).
86,87 miR-486, which has been reported by several investigators to be a tsmiR in gastric cancer, negatively regulates the antiapoptotic glycoprotein OLFM4. 88 Let-7a has reduced expression in gastric cancer tissues and cell lines; [89] [90] [91] its target is RAB40C. miR-137 is a negative regulator of CDC42 and is downregulated in gastric cancer as a result of hypermethylation. 92 Quantitative PCR analyses have confirmed the loss of miR-449 in gastric cancer tissue compared with normal tissue; this miRNA facilitates translation of p53, p21 as well as the apoptosis markers CASP3 and PARP by supressing the oncogenic targets MET, CCNE2, SIRT1 and CDK6. 93 More details are shown in Figure 2 and Table 3 .
94-102 miRNAs and metastasis of UGICs
MetastamiRs in oesophageal cancer Invasion and metastasis are important for cancer progression. 103 In oesophageal squamous cell carcinoma, several upregulated miRNAs (including miR-25, 38 miR-92a 39 and miR-205 54, 55 ) target CDH1 to promote EMT. In addition to regulating EMT, many meta stamiRs regulate targets that promote invasion and metastasis of tumour cells (Figure 1) . In human oesophageal cancer lines, miR-10b promotes migration and invasion through the tumour suppressor KLF4, 40 while miR-10a controls cell migration and invasion by targeting homebox genes.
55 miR21 is also involved in invasion and meta stasis of oesophageal squamous cell carcinoma by targeting PDCD4 in vitro; furthermore, patients with oesophageal squamous cell carcinoma with lymph-node metastasis or venous invasion showed higher expression of miR-21 in comparison with patients without meta stasis or venous invasion. 37 Anti-miRNA-21 transfected cells showed marked reductions in cellular proliferation and invasion. 37 miR-133a targets CD47 to inhibit tumorigenesis and metastasis in vivo, 52 and miR-375 inhibits invasion and metastasis by targeting IGFLR1 and PDK1. 49, 51 In addition, reduced expression of the miR-143/145 cluster (which regulates FSCN1) in oesopha geal squamous cell carcinoma is associated with lymph-node metastases.
62 miR-223 inhibits tumour migration and invasion by targeting ubiquitin ligase FBXW7 and ARTN in this cancer. 42, 61 A significant inverse correlation between miR-200 family expression and ZEB1 and ZEB2 expression in oesophageal adenocarcinoma has been reported. 30 Feber et al. report the expression of three miRNAs associated with lymph-node metastasis: miR-99b, miR-199a-3p and miR-199a-5p. 104 MetastamiRs in gastric cancer miR-21 promotes invasion and lymph-node metastasis in gastric cancer. 64, 78 miR-196a promotes EMT; 67 overexpression of mir-196b has been reported to induce migration and invasion by inducing EMT, increasing expression of VIM (vimentin) and MMP2, and reducing CDH1 expression.
105 miR-10b is markedly increased in lymphnode metastasis positive gastric cancer tissues compared with lymph-node metastasis-free tumour tissues, and levels were correlated with downregulation of HOXD10 expression. miR-10 overexpression promotes invasion by stimulating RhoC and AKT by targeting HOXD10. 106 Upregulation of miR-27 increased the expression of genes associated with EMT, including ZEB1, ZEB2, SLUG and VIM, while decreasing expression of CDH1. miR-7 has shown anti-metastatic properties by targeting IGF1R and SNAI1 and increasing expression of CDH1; this pathway could, therefore, be a potential therapeutic target in gastric cancer. 108 miR-145 suppresses tumour metastasis by directly targeting CDH2 (N-cadherin) and MMP9 but not MMP2. 109 miR-409-3p reduces tumour cell migration and invasion in vitro and metastases in vivo and is frequently downregulated in gastric cancer. 110 miR-409 targets the pro-metastatic gene RDX to suppress metastasis. miR-335 targets BCLW and SP1 to suppress tumour cell invasion and metastasis and is downregulated in gastric cancer.
111 ROCK1 promotes invasion and metastasis in many tumour types and miR-148a directly binds to the ROCK1 3' untranslated region and inhibits ROCK1 expression, therefore suppressing metastasis.
112 miR-429 targets MYC to inhibit invasion. 84 Overexpression of let-7f can inhibit invasion and migration by targeting MYH9 (a tumour metastasis associated gene). 113 Therapeutic implications of miRNAs in UGICs miRNAS as therapeutic targets Synthetic miRNA mimics that have been developed for other cancer types include small interfering RNA (siRNA)-like oligoribonucleotide duplexes 114 and chemically modified oligoribonucleotides. 115 miRNAs can be inhibited in vitro and in vivo by various modified antisense oligonucleotides called antagomiRs; these mol ecules might, therefore, have a role in cancer treatment. 116 Intensive efforts have been made to develop miRNA-based therapeutics in preclinical models of breast cancer, pancreatic cancer and prostate cancer to modify oncogene or tumour suppressor functions. 6, 117, 118 miRNA-based therapeutics are lagging behind for UGICs, but this is a promising area of research.
Modifying chemoresistance
In oesophageal squamous cell carcinoma, cisplatin induces expression of TFAP2A, which confers chemosensitivity by promoting apoptosis; TFAP2A is a target of the miR-200b/200c/miR-429 cluster, which negatively regulates TFAP2A to induce cisplatin resistance. 48 A similar study suggests that overexpression of miR-200c causes cisplatin resistance in oesophageal squamous cell carcinoma cells by upregulating the AKT pathway. 47 miR-141 sensitizes oesophageal squamous cell carcinoma cells to cisplatin by targeting the 3'-untranslated region of YAP1, which is known to have a crucial role in apoptosis induced by DNA-damaging agents.
119 miR-148a upregulation in both oesophageal squamous cell carcinoma and oesophageal adenocarcinoma cells increases sensitivity to cisplatin and 5-fluorouracil. 120, 121 More detailed studies are needed to elucidate these mechanisms.
Zhu et al. 101 showed that the miR-200b/200c/miR-429 cluster sensitized gastric cancer cells (by increasing apoptosis) to vincristine and cisplatin by targeting BCL2 and XIAP. Overexpression of miR-497 sensitized SGC7901/ VCR and A549/CDDP gastric cancer cells to vincristine, 5-fluorouracil and cisplatin by targeting BCL2 in vitro. 99 In vivo experiments and subsequent clinical development is needed.
miRNAs as biomarkers in UGICs
Diagnostic markers miRNAs are stably expressed in serum, plasma, urine, saliva and other bodily fluids, 18 and this property can be exploited. However, little work has been done in this regard in UGICs. In patients with oesophageal squamous cell carcinoma, miR-1322 levels are higher in serum and tumour tissues than in controls, so this miRNA could serve as a biomarker. 22 OncomiRNAs (miR-21/miR-184/ miR-221) and one tsmiR (miR-375) have been studied in the plasma of 50 patients with oesophageal squamous cell carcinoma and 20 healthy volunteers; the plasma level of miR-21 tended to be higher in patients with oesophageal squamous cell carcinoma (P = 0.0649), whereas that of miR-375 was significantly lower (P <0.0001) and the miR-21:miR-375 ratio was significantly higher (P <0.0001) in patients with oesophageal squamous cell carcinoma than in controls. 50 In gastric cancer, three serum miRNAs (miR-221, miR-744 and miR-376c) could distinguish patients with gastric cancer from healthy controls with 82.4% sensitivity and 58.8% specificity. 122 Moreover, levels of miR-221 and miR-376c demonstrated positive correlation with poor differentiation of gastric cancer. 122 In a validation experiment, plasma levels of miR-451 and miR-486 were higher in patients with gastric cancer compared with healthy controls, with high area under the curve (AUC) values (0.96 and 0.92). 123 A genome-wide miRNA profile identified high serum levels of miR-378 in patients with gastric cancer, and validation yielded a high receiver operating characteristic AUC (0.86). 124 A quantitative real-time PCR analysis identified five serum miRNAs (miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p) as biomarkers for gastric cancer, and levels correlated with tumour stage. 125 
Prognostic markers
Although prognostic biomarkers are of less value than predictive or early detection markers, here we describe the literature briefly. miR-21 seems to be a reliable poor prognosticator for oesophageal adenocarcinoma, oesophageal squamous cell carcinoma and gastric cancer. 31, 126, 127 High levels of miR-92a, miR-99b and miR-199a in both oesophageal adenocarcinoma and oesophageal squamous cell carcinoma are also poor prognosticators. 104 Reduced expression of miR-375, miR-203 and miR-205 is associated with late stages of oesophageal adenocarcinoma and oesophageal squamous cell carcinoma. 29, 32 High serum levels of miR-31 in patients with oesophageal squamous cell carcinoma portend poor prognosis. 43 The serum ratio of miR-21:miR-375 correlates with disease recurrence. 50 In gastric cancer, overexpression of miR-93 is associated with short survival. 73 Overexpression of miR-10b, miR-107/196a and miR-223 correlates with metastasis status. 78 High expression of circulating miR-17-5p/20a was an independent poor prognostic factor. 77 Low-level expression of Let-7a/let-7g/let-7f is associated with poor prognosis. 89, 102 miR-181b and miR-182 are also novel poor prognosticators. 79 Low expression levels of miR-125a-3p were found to be associated with enhanced malignant potential such as tumour size, lymph node and liver metastasis and poor prognosis, and this study suggests miR-125a-3p is a potent prognostic marker in gastric cancer. 128 miR-409-3p was found to be downregulated frequently in patients with gastric cancer, and its expression was associated with distant metastasis. 110 Collectively, many miRNAs demonstrate markedly different expression levels between patients with cancer and control groups, and might serve as prognostic markers for monitoring disease status. However, large casecontrol studies are needed to validate these individual miRNA markers as useful clinical tools.
miRNAs and cancer stem cells
Emerging evidence indicates that deregulation of miRNAs has an important role in regulating cancer stem cells of organs such as the breast, 129, 130 brain (glioma) 131 and prostate. 6 Research to establish the role miRNAs have in regulating cancer stem cells in UGICs is needed.
Conclusions
miRNAs are ubiquitous and plentiful, and are crucial post-transcriptional regulators of human gene expression. Research over the past 10 years has identified numerous miRNAs that have diverse roles at multiple steps of tumour progression and metastasis. However, these discoveries have not been translated into the clinics to help patients with UGICs. Considerably more research is needed, including the demonstration of functional consequences in genetically engineered mouse models. The clinical potential is enormous as miRNAs might provide tools for diagnosis, early detection, prediction and monitoring of therapy, and as therapeutic targets. Overall, this area of research has huge potential and should be actively pursued. Furthermore, discoveries made through the ENCODE (Encyclopedia of DNA Elements) project seem extremely relevant to miRNA research. [132] [133] [134] [135] The interim results of the ENCODE project suggest that only up to 3% of the genome codes for proteins and 76% of the genome codes for RNA elements (including miRNAs), which probably regulate the protein coding genes. Many other discoveries, which are outside the scope of this Review, demonstrate that we must focus on the non-protein-coding genome with the same vigour as we have focussed on the protein-coding genome.
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